Dice Thinks It Holds An Ace With Oral IL-17 Inhibitor In Psoriasis
Executive Summary
The company believes it has a potential best-in-class oral drug for psoriasis in development following positive first-in-human clinical trial data. A larger Phase II study is needed.
You may also be interested in...
Lilly Wants To Gamble On Dice’s Oral IL-17 Drugs For Psoriasis
Lilly agrees to pay about $2.4bn to acquire Dice and its Phase IIb oral IL-17 inhibitor, as well as a discovery platform that has yielded a preclinical oral PD-L1 inhibitor.
BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu
Chief commercialization officer Chris Boerner said BMS plans to replace Otezla as the oral standard of care for moderate-to-severe psoriasis with Sotyktu (deucravacitinib); its list price is about 40% higher than Amgen’s product.
Sanofi Partnership On Oral IL-17 Could Be Turning Point For C4XD
The UK drug discovery specialist has made slow progress until now, but the Sanofi deal could yield a challenger in the competitive psoriasis field.